Objective To investigate the usage of cutaneous-muscular flap in the treatment of leg long segmental osteonecrosis.MethodOsteonecrosis models of tibia was made in 48 rabbits and divided randomly into control goup of tibia necrotic bone covered with free skin graft and experimental group with cutaneous-gastrocnemius flap. All of them were examined with ECT, radiograph, osteocalcin measurement and histological observation in 2, 4, 8, 12 weeks postoperatively. Treatment of tibia long segmental necrosis with covering of cutaneous-gastrocnemius flap in 436 patiens were reviewed.ResultAbsorptive radioactivity in arterio-phase and delay-phase of ECT in experimental group were higher than those in control group(P

Objective To investigate the correlation between the-1562 C/T polymorphism of matrix metalloproteinase-9 (MMP-9) and the risk of ischemic stroke.Methods All the relevant literatures published were searched from PubMed,Embase,MEDLINE,Web of Science as well as CBMdisc and CNKI before May 2013.After extracting data,a meta-analysis of the studies meeting the requirements was conducted by using Review Manager Version 5.0 and Stata 11.0 software.The effect size was pooled and odds ratio (OR) and 95％ confidence interval (CI) were calculated.Results Six studies were enrolled,including 1115 patients and 979 controls.The ORs after pooled analysis (95％ CIs) were C/T vs.C/C:1.10 (0.71-1.71) and T/T vs.C/C:1.78 (0.89-3.57) of the codominant genetic model,respectively; C/T + T/T vs.C/C:1.13 (0.76-1.67) of the dominant genetic model; T/T vs.C/T + C/C:1.79 (0.90-3.57) of the recessive genetic model,which suggested that there was no significant correlation between the-1562 C/T polymorphism of MMP-9 gene and the risk of ischemic stroke.The analysis of 5 studies in Chinese populations showed that the ORs (95％ CIs) of the above 4 genetic models were 1.24 (0.76-2.04),1.43 (0.52-3.92),1.25 (0.80-1.97),and 1.33 (0.49-3.62),respectively.There were also no significant differences.Conclusions According to the analysis of the available literatures,there was no significant correlation between the-1562 C/T polymorphism of MMP-9 gene and the risk of ischemic stroke.

Objective To investigate the clinical efficacy of prucalopride in the treatment of severe chronic constipation.Methods The clinical data of 60 patients with severe chronic constipation [slow transit constipation (STC), functional defecation disorder (FDD) and constipation-predominant irritable bowel syndrome (IBS-C)] who were admitted to the Third Affiliated Hospital of Nanjing University of Chinese Medicine from February to August 2014 were prospectively analyzed.A prospective, clinical observational study was performed.Treatment plans included that patients withdrew the initial treatments of laxative and exema and took orally 2 mg prucalopride once daily for 2 weeks, and continued to be treated by oral prucalopride if frequency of the spontaneous complete bowel movement (SCBM) per week was satisfactory (or improvement of symptoms was more than 50％) till 4 weeks, and then were followed up after stopping prucalopride.If improvement of symptoms was less than 50％ after 2-week treatment, other treatment plans were performed according to symptoms of patients from week 3 to week 6 : (1) for patients with STC, prucalopride + two chain bacillus subtilis probiotic capsules were administered orally if patients were satisfied with frequency of SCBM per week and without improvement of abdominal distension;prucalopride + Chinese herb decoction were administered orally if patients had improvement of frequency of SCBM per week with abdominal distension or poor stool output;oral prucalopride + acupuncture were administered if patients were unsatisfied with frequency of SCBM per week or less bowel movements and without improvement of abdominal distension or poor stool output.(2) For patients with FDD, oral prucalopride + acupuncture + biofeed-back therapy were administered.(3) For patients with IBS-C, prucalopride + two chain bacillus subtilis probiotic capsules were administered orally if patients had abdominal distension;prucalopride Chinese herb decoction were administered orally if patients had improvement of frequency of SCBM per week and no improvement of abdominal distension or poor stool output.All patients used a diary for recording the frequency of SCBM per week, stool consistence, exertion in defecation and adverse reactions, which was submitted to doctors for inputting data at the return visit weekly.Results There was good overall medicine compliance in patients.Of 60 patients, 43 patients completed treatments (21 with STC, 11 with FDD and 11 with IBS-C).After 2-week treatment, there were 19 patients with satisfied therapeutic effects, 14 with improvement of constipation and 10 with poor therapeutic effects.After 4-week treatment, constipation in 17 patients was cured, constipation in 18 patients was improved,and constipation in 8 patients was not improved.Nineteen of 60 patients were complicated with adverse reactions within 1 week of the medication, including 6 patients dropping out of the trial due to medication withdrawal and others with improvement by symptomatic treatment or spontaneous remission.Conclusions Prucalopride is effective for the treatment of severe chronic constipation with a good toleration, and it can improve the overall satisfaction of patients combined with Chinese herb decoction and acupuncture.

The impact of plateau environment on cerebral venous thrombosis (CVT) is more complex and diverse than in plain areas. This article reviews the epidemiological characteristics, affected sites, and especially the pathogenesis of CVT in plateau areas.